News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
815,087 Results
Type
Article (74196)
Company Profile (643)
Press Release (740248)
Multimedia
Podcasts (123)
Webinars (14)
Section
Business (226498)
Career Advice (3716)
Deals (39172)
Drug Delivery (129)
Drug Development (89011)
Employer Resources (198)
FDA (17809)
Job Trends (17085)
News (386141)
Policy (38645)
Tag
Academia (2999)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (94)
Alliances (55842)
ALS (102)
Alzheimer's disease (1503)
Antibody-drug conjugate (ADC) (161)
Approvals (17769)
Artificial intelligence (303)
Autoimmune disease (29)
Automation (16)
Bankruptcy (402)
Best Places to Work (12632)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (439)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (308)
Cancer (2465)
Cardiovascular disease (210)
Career advice (3166)
Career pathing (34)
CAR-T (175)
Cell therapy (487)
Cervical cancer (22)
Clinical research (71979)
Collaboration (928)
Company closure (1)
Compensation (572)
Complete response letters (30)
COVID-19 (2867)
CRISPR (50)
C-suite (274)
Cystic fibrosis (109)
Data (2334)
Decentralized trials (2)
Denatured (40)
Depression (56)
Diabetes (302)
Diagnostics (6920)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (132)
Drug pricing (128)
Drug shortages (33)
Duchenne muscular dystrophy (103)
Earnings (93537)
Editorial (45)
Employer branding (25)
Employer resources (167)
Events (128812)
Executive appointments (785)
FDA (19192)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (822)
Gene editing (125)
Generative AI (27)
Gene therapy (361)
GLP-1 (855)
Government (5114)
Grass and pollen (6)
Guidances (108)
Healthcare (20871)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (150)
Indications (30)
Infectious disease (3030)
Inflammatory bowel disease (159)
Inflation Reduction Act (11)
Influenza (58)
Intellectual property (102)
Interviews (727)
IPO (17726)
IRA (51)
Job creations (4939)
Job search strategy (2589)
Kidney cancer (11)
Labor market (44)
Layoffs (558)
Leadership (24)
Legal (9887)
Liver cancer (82)
Lung cancer (347)
Lymphoma (160)
Machine learning (8)
Management (65)
Manufacturing (358)
MASH (78)
Medical device (14620)
Medtech (14625)
Mergers & acquisitions (22006)
Metabolic disorders (801)
Multiple sclerosis (88)
NASH (23)
Neurodegenerative disease (116)
Neuropsychiatric disorders (34)
Neuroscience (2114)
NextGen: Class of 2025 (7634)
Non-profit (5080)
Now hiring (41)
Obesity (431)
Opinion (275)
Ovarian cancer (80)
Pain (104)
Pancreatic cancer (91)
Parkinson's disease (161)
Partnered (22)
Patents (256)
Patient recruitment (119)
Peanut (51)
People (63840)
Pharmaceutical (132)
Pharmacy benefit managers (22)
Phase I (22245)
Phase II (31401)
Phase III (23686)
Pipeline (1329)
Policy (177)
Postmarket research (3239)
Preclinical (9800)
Press Release (72)
Prostate cancer (114)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (433)
Real estate (7112)
Recruiting (75)
Regulatory (25995)
Reports (57)
Research institute (2655)
Resumes & cover letters (579)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (82)
Series A (143)
Series B (94)
Service/supplier (26)
Sickle cell disease (59)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4188)
State (2)
Stomach cancer (16)
Supply chain (75)
Tariffs (51)
The Weekly (81)
Vaccines (819)
Venture capitalists (44)
Weight loss (306)
Women's health (37)
Worklife (20)
Date
Today (308)
Last 7 days (902)
Last 30 days (3092)
Last 365 days (35160)
2025 (12134)
2024 (37887)
2023 (42567)
2022 (53926)
2021 (58722)
2020 (57663)
2019 (51302)
2018 (39083)
2017 (36786)
2016 (37675)
2015 (43661)
2014 (38254)
2013 (34183)
2012 (36131)
2011 (36206)
2010 (35534)
Location
Africa (1186)
Alabama (60)
Alaska (7)
Arizona (244)
Arkansas (14)
Asia (48544)
Australia (8331)
California (6570)
Canada (2085)
China (570)
Colorado (287)
Connecticut (302)
Delaware (163)
Europe (109653)
Florida (959)
Georgia (222)
Hawaii (1)
Idaho (63)
Illinois (622)
India (30)
Indiana (337)
Iowa (12)
Japan (173)
Kansas (110)
Kentucky (28)
Louisiana (15)
Maine (70)
Maryland (981)
Massachusetts (5044)
Michigan (248)
Minnesota (425)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (67)
New Hampshire (69)
New Jersey (1856)
New Mexico (31)
New York (1854)
North Carolina (1135)
North Dakota (9)
Northern California (2822)
Ohio (223)
Oklahoma (15)
Oregon (46)
Pennsylvania (1446)
Puerto Rico (13)
Rhode Island (36)
South America (1561)
South Carolina (26)
South Dakota (1)
Southern California (2433)
Tennessee (106)
Texas (981)
United States (25124)
Utah (196)
Virginia (174)
Washington D.C. (72)
Washington State (606)
West Virginia (3)
Wisconsin (70)
815,087 Results for "nippon kayaku co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku for Taletrectinib in Japan
AnHeart Therapeutics today announced it has entered into an exclusive license agreement with Nippon Kayaku Co., Ltd (“Nippon Kayaku”) to market and distribute AnHeart’s lead investigational therapy, taletrectinib, in Japan.
October 30, 2023
·
6 min read
Press Releases
Amaran Biotech Signs MOU with Nippon Fine Chemical
March 7, 2025
·
3 min read
Business
epitoMAP Inc., Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co., Ltd. Enter into License Agreement
epitoMAP Inc. and Animal Allergy Clinical Laboratories Inc. entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. on November 10, 2023.
November 17, 2023
·
2 min read
Business
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases
MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need.
April 4, 2024
·
3 min read
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
Vicore Pharma Holding AB, unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, announced it has entered into an exclusive licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company, to develop and commercialize Vicore’s drug candidate C21 in Japan.
February 9, 2024
·
4 min read
Press Releases
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
January 27, 2025
·
5 min read
Press Releases
Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan
November 13, 2024
·
5 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Press Releases
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
March 13, 2025
·
3 min read
1 of 81,509
Next
